November 2020 Vol 11, No 11
With high recurrence and mortality rates, ovarian cancer often has a devastating impact on patients and their loved ones.
The National Accreditation Program for Breast Centers (NAPBC)/American College of Surgeons is dedicated to promoting improved treatment outcomes for breast disease.
Changes in Body Composition and Fatigue in Cancer Survivors During a 12-Week Supervised Exercise Oncology Rehab Program
Pamela Cloys, MSN, ANP-C, Jason Morrow, RN, BSN, OCN, Noreen Denham, RN, OCN, Regina Franco, MSN, ANP-C, Jeff Giguere, MD, Armand DeSollar, BS, Tanner Huyck
The “Moving On” Oncology Rehabilitation program is a free 12-week exercise program for cancer survivors located at the Prisma Health Cancer Institute Center for Integrative Oncology & Survivorship.
Jessica MacIntyre, APRN, NP-C, AOCNP, Sophie Torrents, MHA, Nancy Farfan, BSN, RN, Aixa Figueroa, Gilbert Pebanco, RN
Sylvester Comprehensive Cancer Center (SCCC) at the University of Miami is an academic medical center in Miami, FL.
Implementation of a Nurse Navigation On-Demand Telehealth Pilot Program at Sylvester Comprehensive Cancer Center, SOON Program
Sylvester Comprehensive Cancer Center (SCCC) at the University of Miami is 1 of only 2 cancer centers that have been recognized by the National Cancer Institute in Florida.
Improving Non–Small-Cell Lung Cancer Care Delivery: Findings for Oncology Nurses and Patient Navigation from a National Quality Survey
Oncology nursing and patient navigation are vital components of optimal cancer care planning, coordination, and delivery within multidisciplinary teams (MDTs).
Early-stage and hormone receptor–positive breast cancers may need additional genomic testing to determine which patients need chemotherapy in addition to endocrine therapy.
Insights on Bone Health Awareness and Education from Cancer Patients at Risk for Skeletal-Related Events: Findings from a Patient-Centric Survey
Katherine B. Carlson, PhD, Kimberly Lowe, PhD, Basia Bachmann, Benoit Cadieux, PhD, Darcy R. Flora, PhD, David C. Fuehrer, Guy Boike, MD
Cancer patients with bone metastasis or multiple myeloma (MM) are at increased risk for painful and irreversible bone complications known as skeletal- related events (SREs), which include bone fractures, spinal cord compression, and radiation or surgery to the bone.
As a member of the Cancer Care Committee at a community hospital, the thoracic oncology nurse navigator (ONN) recognized the need for a quality study investigating the process for cancer patients receiving PEG tube placement.
Key Findings from a Survey and Interviews with AONN+ Local Navigator Network Leaders on Building and Sustaining Networks
The ACS received grant funding from the Merck Foundation to explore navigator network development, implementation, and sustainability.
A professional steering committee for Great Lakes Health Hospital System identified the need to coordinate and integrate an organized oncology service line and attain Commission on Cancer accreditation.
The first cases of COVID-19 in the United States were reported in early January 2020 and began rapidly increasing in March 2020.
Oncology nurse navigators and administrative staff reported spending more than half their daily shifts in some way managing incoming calls and the backlog of voicemails.
Navigating Uninsured Lung Cancer Patients: One Thoracic Oncology Nurse Navigator’s Experience in Removing Financial Barriers
One recent study revealed that lung cancer was the most common cancer among those uninsured.
Acalabrutinib vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
Paolo Ghia, MD, Andrzej Pluta, MD, Malgorzata Wach, MD, Daniel Lysak, MD, Tomas Kozak, MD, Martin Simkovic, MD, Polina Kaplan, MD, Iryna Kraychok, MD, Arpad Illes, MD, Javier de la Serna, MD, Sean Dolan, MD, Philip Campbell, MD, Gerardo Musuraca, MD, Abraham Jacob, MD, Eric J. Avery, MD, Jae Hoon Lee, MD, Denise Wang, Priti Patel, MD, Wojciech Jurczak, MD
Acalabrutinib is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with CLL, including those with R/R CLL.
Characteristics of Patients with a Complete Response Treated with Dabrafenib plus Trametinib Combination Therapy: Findings from Pooled COMBI-d and COMBI-v 5-Year Analysis
Caroline Robert, MD, PhD, Jean-Jacques Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, MD, Evgeny Levchenko, Vanna Chiarion Sileni, MD, Jacob Schachter, MD, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, MD, Dirk Schadendorf, MD, Georgina V. Long, MD, PhD
Two large phase 3 studies (COMBI-d [NCT01584648] and COMBI-v [NCT01597908]) evaluated the efficacy and safety of oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (D+T) as first-line therapy in patients (pts) with BRAF V600E- or V600K-mutant unresectable or metastatic cutaneous melanoma.
Characterization and Management of Adverse Reactions in Patients with Endometrial Carcinoma Receiving Lenvatinib plus Pembrolizumab (Study 111/KEYNOTE-146): Nurse Roles in Patient Education and Adverse-Reaction Management
Krysten Soldan, RN, Carolyn Johns, NP, Matthew H. Taylor, MD, Kathryn Gillis, PharmD, Robert Orlowski, MD, Min Ren, Vicky Makker
Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).
Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere – An Analysis of US Clinical Data
Tina DeNofrio, RN, BSN, OCN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Julia Vandross, NP-BC, BSN, MSN
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used androgen deprivation therapy (ADT) for prostate cancer (PCa).
Improving Quality of Cancer Care by Integrating Considerations of Shared Importance to Patients and Family Caregivers into Clinical Pathway Platforms
Dena Schulman-Green, PhD, Emily Cherlin, PhD, MSW, Renee Capasso, BS, Sarah S. Mougalian, MD, Shiyi Wang, MD, PhD, Cary P. Gross, MD, Preeti S. Bajaj, PhD, Katherine Eakle, PharmD, Sharmi Patel, PharmD, Kerin Adelson, MD
Clinical pathways have increasingly been incorporated into cancer care, aiming to encourage high-quality, evidence-based care while minimizing costs; however, clinical pathways infrequently incorporate patient and family perspectives, limiting patient-centeredness and value for shared decision-making.
Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Five Years of Follow-Up from the Phase 3 RESONATE-2 Study
Jillian Settlemire, RN, Edythe M. Greenberg, PhD, RN, FNP-BC, Indu Lal, MD, Carlos Amaya-Chanaga, MD, Jan A. Burger, MD, PhD, Steven Coutre, MD
Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.
The Role of the Oncology Nurse Navigator in Establishing an Epic Workflow for Virtual Multidisciplinary Clinics During COVID Restrictions
Laura Beaupre, RN, BSN, OCN, CN-BN, Kathleen Sevedge, RN, MA, AOCN, Angela Miller, RN, BSN, OCN, MEd, Alyssa Pauls, RN, BSN, OCN, Jane Zubia, RN, OCN, CN-BN, Raizalie Roman, RN, BSN, OCN, Maritza Chicas, RN, BSN, OCN, Cynthia Smith, RN, BSN, OCN, MA, Tracy Walczer, RN, BSN, OCN, Jeanne Kenna, RN, OCN, CRNI, Paul Torreson, Eileen Steirer
Oncology nurse navigators and multidisciplinary models of care have been shown to improve outcomes for patients with cancer.
Efficacy of an Electronic Survey to Establish Reconnection, Assessment of Clinical Compliance, and Provision of Resources for a Large Cohort of Hereditary Cancer Patients
Kathryn A. Pratt, BSN, RN, OCN, CBCN, Sayoni Lahiri, MS, CGC, Sara Pirzadeh-Miller, MS, CGC, Parker Read, MS, CGC
The UT Southwestern Cancer Genetics Program implemented a genetic patient navigator (GPN) to assess patients’ barriers to care, assist patients in identifying resources to increase compliance, promote healthy lifestyle education, and assist with coordination of cascade testing for at-risk relatives.
Lung cancer has the highest mortality rate of all tumor sites.
Carla Strom, MLA, Maria Alejandra Combs, JD, OPN-G, Emily Copus, MSW, OPN-CG, Alexis Daniels, MS, OPN-CG, Kelsey Shore, BA, CCRC, Karen Winkfield, MD, PhD
The use of acuity scales to assess cancer patient needs when undergoing treatment is gaining recognition as a way to optimize caseloads for patient navigators (PNs).
How Coordination of Care Along the Diagnostic Continuum Improves Timeliness to Care for Lung Cancer Patients
The process of screening and/or detection to the actual diagnosis of lung cancer involves multiple specialties and diagnostic testing, which can be quite daunting for an individual and his/her family.
Impact of a National Clinical Trial Nurse Navigation Service on Trial Enrollment for Patients with a Hematologic Malignancy
Low enrollment rates for cancer clinical trials have been an ongoing barrier to scientific advances in oncology care.
Leveraging Mobile Phone Navigation for Cancer Care Continuity and Support During the COVID-19 Pandemic at Kenyatta National Hospital
Catherine Nyongesa, MbChB, FC RAD ONCO, MMED RAD ONC, Anastacia Bosire, MScN Onco, Grace Omulogoli, BSc, HSM, Ronniey Obulemire, MPH, Hayley Freedman, MPH, Erica Krisel, MPH
Kenyatta National Hospital (KNH) is the main public hospital in Kenya delivering comprehensive cancer care and receives patients from throughout the country.
Page 1 of 2
Results 1 - 30 of 42
Results 1 - 30 of 42